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CORTICOSTEROIDS AND ALCOHOLIC HEPATITIS 
Imperiale TF, McCullough AJ. Do corticosteroids 
reduce mortality from alcoholic hepatitis. Ann Intern 
Med 1990;113:299-307. 
EDITOR’S ABSTRACT 
The purpose of the study was to determine whether 
corticosteroids affect short-term mortality from alco- 
holic hepatitis. A metanalysis was conducted using 
studies identified through a MEDLINE computer 
search from 1966 to 1989 and extensive manual 
searches of associated bibliographies. Eleven ran- 
domized studies that assessed mortality in hospitalized 
patients diagnosed with alcoholic hepatitis and 
treated with corticosteroids were evaluated. Overall, 
the protective efficacy of corticosteroids was 3770 (95% 
confidence interval 20% to 50%). Protective efficacy 
was higher among those trials with higher quality 
scores and in trials that excluded subjects with active 
gastrointestinal bleeding in patients with hepatic en- 
cephalopathy, protective efficacy was 34% overall (con- 
fidence interval 15% to 48%). In subjects without 
hepatic encephalopathy, corticosteroids were not be- 
lieved to have a protective effect; this lack of efficacy 
was noted across all trial subgroups. Results of the 
metanalysis suggest that corticosteroids reduce short- 
term mortality in patients with acute alcoholic hepa- 
titis who have hepatic encephalopathy. The protective 
effect is dependent on exclusion of patients with acute 
gastrointestinal bleeding. 
COMMENTS 
This important metanalysis responds, a t  least tempo- 
rally, to an editorial published in the same journal 
almost a year earlier calling for a metanalysis of the 
benefit of corticosteroids in the treatment of alcoholic 
hepatitis (1). The most widely accepted therapy for acute 
alcoholic hepatitis is general supportive care. Research 
into the mechanism of liver injury from alcohol has lead 
to the treatment of alcoholic hepatitis with a number of 
agents, including propylthiouracil, anabolic steroids and 
corticosteroids. The latter has been the most intensively 
studied, starting with a report in 1971 of a randomized 
controlled study terminated early by the investigators 
because of the overwhelming protective effect found for 
corticosteroid use in encephalopathic patients with 
alcoholic hepatitis (2). A succession of randomized 
controlled trials followed, two of which showed sig- 
nificant improvement in survival with steroids and 
seven of which did not. In 1989 a multicenter trial found 
a substantial benefit from steroid treatment in a 
population of patients selected for encephalopathy or 
high prothrombin times and bilirubin levels (3). 
Combining results from multiple trials allows a 
metanalysis to achieve large sample sizes and statisti- 
cally significant results where individual trials have 
failed to do so. Accumulating a large sample size in this 
manner is easy relative to the difficulty of conducting a 
large clinical trial. However, to prevent the sample size 
from giving the reader false confidence in the results of 
the analysis, the methodology of the metanalysis as- 
sumes an even greater significance for both authors and 
readers. Imperiale and McCullough carefully follow the 
emerging standards for the performance of a met- 
analysis by specifying the literature-search methods, 
supplying a list of rejected trials, describing the criteria 
for the quality review of the articles and describing 
standards for deciding if the trials may be appropriately 
aggregated. 
Although the authors adhere to many of the standards 
of metanalysis methodology, in a few areas their meth- 
odology could be more rigorously described. It is very 
important for a metanalysis to use all available studies 
done on the research question. Imperiale and McCul- 
lough describe their use of a computerized database, 
textbook references and references from the articles 
retrieved by the first two methods. A more complete 
search would have specified the use of a professional 
librarian to perform the computer search, as skill in 
using these databases varies widely. Other sources for 
finding references recommended in the literature on 
metanalysis include Current Contents, databases of 
unpublished material and polls of senior researchers in 
the field (4). The latter two sources are important for 
addressing the issue of publication bias or the selective 
appearance in the published literature of trials with 
positive results. The authors’ case for the lack of 
publication bias, on the grounds that a large proportion 
of the studies found no significant difference in the 
study groups, is not compelling. Although the question 
of how to include unpublished studies in a pooled 
analysis is complicated, a simple sensitivity analysis can 
be done to determine how many unpublished negative 
trials (of good quality) would be required to render the 
result of the pooled analysis statistically insignificant. 
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FIG. 1. Plot of mortality in the treatment vs. control groups in each 
of the eleven studies included in the metanalysis. A pooled protective 
efficacy of 37% was found for corticosteroid treatment in acute 
alcoholic hepatitis. The one outlier was excluded. The area of the data 
points is proportional to the study sample size. 
Rosenthal (5) in 1980 suggested an equation based on 
the Z scores of the pooled studies that, when applied to 
this metanalysis, would suggest that more than 50 
insignificant unpublished studies would be required to 
raise the p value of the primary result over 0.05. Thus 
the confidence of the reader in the completeness of a 
search can usually be improved by a more detailed 
description of sources used and application of sensitivity 
analysis to the issue of publication bias. 
Also missing from the description of the design of this 
metanalysis is mention of whether the people selecting 
a paper for inclusion and assessing its quality were 
blinded to the authors and the journal in which it 
appeared. Additionally, no information is presented on 
the reliability of the data extraction step. Finally, the 
pooled studies do not consistently use an intention-to- 
treat analysis. For example, a number of deaths were 
withdrawn from analysis by the authors of the original 
trials, either because the deaths occurred early in the 
course of the experimental treatment or because the 
subjects did not complete the treatment protocol. Some 
of these deaths are retained in the results of the studies 
and some are excluded. The methods section of the 
metanalysis does not address this issue. These are 
important sources of potential bias. 
The fundamental question addressed in a metanalysis 
is whether the conflicting findings of different experi- 
ments represent a chance event or the application of a 
treatment to more than one population. In evaluating 
the homogeneity of the treatment populations the au- 
thors very appropriately rely first on graphic methods. 
We have reproduced their graph of mortality rates in the 
control vs. treatment group with an enhancement using 
the area of the data points to represent the sample size of 
each of the pooled experiments. A line representing the 
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FIG. 2. Plot of mortality in the treatment vs. control groups for the 
subgroup of patients with hepatic encephalopathy. A pooled protective 
efficacy of 34% was found. 
average protective efficacy of prednisone (37% protective 
efficacy) reported in the paper is superimposed over the 
data points (Fig. 1). Using a graphic presentation of the 
data gives the reader much more information than does 
the summary measure of treatment effect. In fact, one 
can see that graphically, two populations might be 
present; one consisting of seven studies lying close to the 
no-treatment effect line and four studies lying along a 
line of much steeper slope close to they axis. If under- 
lying differences in the methodology, study population 
or treatment intervention supported this division, one 
might decide not to pool all 11 studies. The other 
available information about these studies, in fact, does 
not support this division. The graphic outlier, rather, is 
also found to have an extremely low methodological 
quality score. When it is removed, the remaining studies 
satisfy a statistical test of homogeneity, which is the 
second step in the analysis. In metanalyses of small 
numbers of studies, the power to reject the null hy- 
pothesis of homogeneity is low; thus graphic methods 
are stressed as a way of searching for possible heteroge- 
neity in study populations (4,6). 
This metanalysis is particularly strengthened by its 
secondary analyses. The presence of hepatic encepha- 
lopathy was hypothesized to predict treatment efficacy 
and a separate analysis of subjects who have encepha- 
lopathy found that virtually all treatment benefit was 
confined to this group (Fig. 2). Likewise, study-level 
hypotheses predicted that studies that did not exclude 
subjects with gastrointestinal bleeding and were of lower 
quality would show less of a treatment effect. These 
hypotheses were also borne out by the subgroup 
analysis. This consistency in the distribution of 
treatment effects is very compelling evidence supporting 
the authors’ conclusions. 
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The authors present strong support for the use of 
corticosteroids for the treatment of alcoholic hepatitis 
in patients with hepatic encephalopathy if the goal is to 
improve 30-day survival. The significance of these 
findings is lessened by two factors. First, this is a 
relatively select group of patients. In the 1989 multi- 
center trial mentioned above, it was estimated that each 
participating academic medical center would only admit 
five or six such patients per year. Second, the long-term 
survival of these patients is unknown. Several of the 
pooled studies described late deaths (at 1 to 3 mo) that 
might well have been steroid complications. Thus, late 
complications of therapy or an overall poor prognosis 
could eliminate the treatment benefit of steroids if a 
longer survival period was stipulated. 
The authors have made an important contribution to 
the question of corticosteroid use in alcoholic hepatitis. 
They have both described the state of the experimental 
literature in a structured way and have quantified a 
treatment effect in a particular subgroup. The priority 
for future research is to work on refining the definition 
of the subgroup(s) that benefit from corticosteroids and 
to determine whether the treatment effect persists for a 
reasonable length of time beyond 1 mo. 
TIMOTHY HOFER, M.D. 
LAURENCE MCMAHON, M.D. 
University of Michigan Medical Center 
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